Nifedipine Tablet, Extended Release
Product Images NDC 71610-689

The text provides data on mean reductions in trough supine blood pressure in mmHg achieved using Nifedipine extended-release tablets at various dosages. The data is taken from two different studies with different numbers of participants (N) and includes systolic and diastolic blood pressure measurements. The text indicates that the placebo response has been subtracted from the results.*

This is a comparison of adverse effects experienced by patients who used Nifedipine extended-release tablets versus those who received placebo treatment. In the group of 370 patients who used the medication, the most commonly reported adverse effect was headache, with a percentage of 19%. Flushing/heat sensation, dizziness, fatigue/asthenia, nausea, and constipation were also reported but with lower percentages. In the group of 126 patients who received placebo treatment, headache was also the most common adverse effect, although with a lower percentage than in the Nifedipine group. Flushing/heat sensation, dizziness, fatigue/asthenia, and nausea were also reported but with a lower prevalence.*

The text describes different strengths of Novast pills with color and marking information for identification purposes. The strengths mentioned are 30 mg (yellow), 60 mg (pink), and 90 mg (brown). Each tablet has a unique marking on one side with Novast brand name.*